C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use
US-10689401-B2 · Jun 23, 2020 · US
This page is not indexed by search engines while we improve data quality.
Dai Xing patents
Dai Xing holds 16 patents in our database, with recent filings and technology areas summarized below.
| Metric | Value |
|---|---|
| Total patents | 16 |
| Recent patents | 0 |
| First publication | Apr 14, 2015 |
| Latest publication | Jun 23, 2020 |
Filing trend
Year-over-year patent counts for this assignee.
Recent patents
Latest publications where this party is an assignee.
C5-C6-Oxacyclic Fused Iminothiazine Dioxide Compounds Bearing an Ether Linker as BACE Inhibitors, Compositions, and Their Use
US-2019016734-A1 · Jan 17, 2019 · US
Compounds inhibiting leucine-rich repeat kinase enzyme activity
US-9718818-B2 · Aug 1, 2017 · US
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
US-9573939-B2 · Feb 21, 2017 · US
Iminothiadiazepane Dioxide Compounds as BACE Inhibitors, Compositions, and Their Use
US-2017037056-A1 · Feb 9, 2017 · US
Notable patents
Representative or frequently cited publications from precomputed assignee stats.
C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use
US-10689401-B2 · Jun 23, 2020 · US
C5-C6-Oxacyclic Fused Iminothiazine Dioxide Compounds Bearing an Ether Linker as BACE Inhibitors, Compositions, and Their Use
US-2019016734-A1 · Jan 17, 2019 · US
Compounds inhibiting leucine-rich repeat kinase enzyme activity
US-9718818-B2 · Aug 1, 2017 · US
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
US-9573939-B2 · Feb 21, 2017 · US
Iminothiadiazepane Dioxide Compounds as BACE Inhibitors, Compositions, and Their Use
US-2017037056-A1 · Feb 9, 2017 · US
Technology areas
Mapped technology topics for this assignee.
| Technology | Patents |
|---|---|
| Chemistry & Metallurgy | 16 |
| Human Necessities | 14 |
| Cross-Sectional Technologies | 4 |